The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention
Author:
Affiliation:
1. Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, Madhya Pradesh, India
Publisher
Informa UK Limited
Subject
Molecular Biology,General Medicine,Structural Biology
Link
https://www.tandfonline.com/doi/pdf/10.1080/07391102.2023.2191721
Reference216 articles.
1. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
3. FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium
4. Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies
5. Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Computational biophysical characterization of the effect of gatekeeper mutations on the binding of ponatinib to the FGFR kinase;Archives of Biochemistry and Biophysics;2024-08
2. Regulatory mechanism of the Glabrene against non‐small cell lung cancer by suppressing FGFR3;Environmental Toxicology;2024-03-22
3. Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers;International Journal of Molecular Sciences;2024-01-10
4. Tumor microenvironment diversity and plasticity in cancer multidrug resistance;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-11
5. Sanggenol B, a plant bioactive, as a safer alternative to tackle cancer by antagonising human FGFR;Journal of Biomolecular Structure and Dynamics;2023-08-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3